Now showing items 1-5 of 5

    • Ação do paratormônio humano (1-34) no tecido ósseo de ratas osteopênicas 

      Costa, Rafael Pacheco da [UNIFESP] (Universidade Federal de São Paulo (UNIFESP), 2010-07-27)
      Introduction: Bone remodeling depends upon a variety of systemic and local factors. Systemic factors that have a direct effect include the parathyroid hormone which together with other factors maintains bone homeostasis. ...

    • Baixas concentrações séricas de 25-hidroxivitamina D em crianças e adolescentes com lúpus eritematoso sistêmico 

      Peracchi, Octávio Augusto Bedin [UNIFESP] (Universidade Federal de São Paulo (UNIFESP), 2011-06-29)
      Objective: to evaluate the levels of 25-hydroxivitamin-D (25(OH)D) in children and adolescents with Systemic Lupus Erythematosus (Juvenile SLE [JSLE]) and to associate them with disease duration and activity, use of ...

    • Diagnóstico Laboratorial do Hiperparatiroidismo Primário 

      Hauache, Omar M. [UNIFESP] (Sociedade Brasileira de Endocrinologia e Metabologia, 2002-02-01)
      Primary hyperparathyroidism (PHP) is a frequent endocrinopathy. Increased serum calcium levels may be considered as a potential marker for parathyroid autonomy and this explains why PHP should be routinely investigated in ...

    • Evolution of PTH assays 

      Vieira, José Gilberto H. [UNIFESP]; Kunii, Ilda [UNIFESP]; Nishida, Sônia (Sociedade Brasileira de Endocrinologia e Metabologia, 2006-08-01)
      PTH metabolism is complex and the circulating forms include the intact 1-84 molecule as well as several carboxyl-terminal fragments. The first generation of PTH assays included several types of competitive assays, with ...

    • Paratormônio e osteoporose: encontrando o fio da meada. Bases fisiológicas para utilização do PTH no tratamento da osteoporose 

      Gracitelli, Mauro E.c.; Vidoris, André Alexis C.; Luba, Ricardo; Lazaretti-Castro, Marise [UNIFESP] (Sociedade Brasileira de Endocrinologia e Metabologia, 2002-06-01)
      Parathyroid hormone (PTH) will be available in a few months for the treatment of osteoporosis. When used as a single daily subcutaneous injection for at least 1 year, it increases bone mass and reduces fracture rate more ...